Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Machine Learning Based Predictive Model of 5-Year Survival in Multiple Myeloma Autologous Transplant Patients

Robert Chen, PhD, Sankeerth Garapati, David Wu, Sean Ko, Sam Falk, Djamilia Dierov, Adam Stasiw, Adomah S. Opong, ANP, Kenneth R. Carson, MD PhD

Blood (2019) 134 (Supplement_1): 2156.

https://doi.org/10.1182/blood-2019-129432

Published: 2019

Journal Articles

Prophylaxis of Chemotherapy-Induced Nausea and Vomiting with Fosaprepitant and Granisetron in Pediatric Patients after Allogeneic HSCT

Karin Melanie Cabanillas Stanchi, MSc, Julia Vek, Dr. MD, Patrick Schlegel, MD, Christian M. Seitz, MD, Joachim Rupprecht, Dr. MD, Sarah Schober, Dr. MD, Sebastian Michaelis, Dr. MD, Carmen Malaval, Dr. MD, Tim Flaadt, Dr. MD, Lukas Schnaufer, Dr. MD, Manon Queudeville, Dr. MD, Judith Feucht, Dr. MD, Peter Lang, MD, Rupert Handgretinger, MD PhD, Michaela Döring, Dr. MD

Blood (2018) 132 (Supplement 1): 3388.

https://doi.org/10.1182/blood-2018-99-112762

Published: 2018

Journal Articles

Sinusoidal Obstruction Syndrom (SOS): Warning about Autologous Stem Cell Transplantation (ASCT) Preceded By Regimens Containing Oxaliplatin

Pierre-Edouard Debureaux, Delphine Le Febvre de Nailly, Emmanuelle Tavernier, MD, Manel Bedoui, MD, Frederique Kuhnowski, MD, Jerome Tamburini, MD PhD, Luc Mathieu Fornecker, Herve Tilly, MD, David Sibon, MD PhD, Marie-Pierre Moles, Sylvie Glaisner, MD, Jean Philippe Richardet, MD PhD, Sebastien Mule, MD PhD, Julien Calderaro, MD, Corinne Haioun, MD, Jehan Dupuis, MD

Blood (2018) 132 (Supplement 1): 4597.

https://doi.org/10.1182/blood-2018-99-110728

Published: 2018

Journal Articles

Safety and Efficacy of Single-Dose Intravenous Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients with Hematooncological Malignancies after Moderate and High Emetogenic Chemotherapy

Semjon Willier, MD, Karin Melanie Cabanillas Stanchi, MSc, Martha von Have, Dr. MD, Vera Binder, Dr. MD, Franziska Blaeschke, Dr. MD, Tobias F. Feuchtinger, Prof. Dr. MD, Michaela Döring, Dr. MD

Blood (2017) 130 (Supplement 1): 3220.

https://doi.org/10.1182/blood.V130.Suppl_1.3220.3220

Published: 2017

Journal Articles

Antiemetic Prophylaxis with Granisetron and Fosaprepitant during Moderate and High Emetogenic Chemotherapy in Pediatric Patients

Michaela Döring, Dr. MD, Karin Melanie Cabanillas Stanchi, MSc, Manon Queudeville, Dr. MD, Ulrike Hartmann, Dr., Michael Ost, Dr. MD, Marie-Sarah Koch, Dr. MD, Carmen Malaval, Dr. MD, Markus Mezger, Dr. MD Dr. rer. nat., Sarah Schober, Dr. MD, Simone Weber, Dr. MD, Veit Lange, Dr. MD, Rupert Handgretinger, MD, Martin Ebinger, MD

Blood (2017) 130 (Supplement 1): 3228.

https://doi.org/10.1182/blood.V130.Suppl_1.3228.3228

Published: 2017

Journal Articles

T-Cell Depleted HLA-Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT) Followed By Donor Lymphocyte Infusion with T Cells Transduced with the Inducible Caspase 9 (iC9) Suicide Gene in Children with Hematological Malignancies

Barbarella Lucarelli, MD, Alice Bertaina, MD PhD, Pietro Merli, MD, Concetta Quintarelli, PhD, Daniela Pende, MD, Michela Falco, PhD, Maria Giuseppina Cefalo, MD, Giuseppina Li Pira, PhD, Ignazio Caruana, PhD, Letizia Pomponia Brescia, MD, Luisa Strocchio, MD, Giuseppe Maria Milano, MD, Valentina Bertaina, PhD, Matilde Sinibaldi, PhD, Mattia Algeri, MD, Lorenzo Moretta, MD, Joanna Stanson, Annemarie Moseley, MD PhD, Franco Locatelli, MD

Blood (2016) 128 (22): 4683.

https://doi.org/10.1182/blood.V128.22.4683.4683

Published: 2016

Journal Articles

A Randomized Trial of Olanzapine and Palonosetron versus Infused Ondansetron for the Treatment of Chemotherapy Induced Nausea and Vomiting in Patients Undergoing Hematopoietic Stem Cell Transplantation

Midori Nakagaki, BPharm, MSc, BCOP, Michael Barras, BPharm, GradDipClinPharm, PhD, Cameron Curley, MBBS, FRACP, FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Glen A Kennedy, MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 1910.

https://doi.org/10.1182/blood.V126.23.1910.1910

Published: 2015

Journal Articles

Phase II, Open Label, Randomized Comparative Trial Of Ondansetron Alone Versus The Combination Of Ondansetron Plus Aprepitant For The Prevention Of Nausea and Vomiting In Patients (Pts) With Hematological Malignancies Receiving Regimens Containing High Dose Cytarabine

Talha Badar, MBBS, FCPS, Gloria Mattiuzzi, MD, Hagop M Kantarjian, MD, Farhad Ravandi, MD, Naval G. Daver, MD, Guillermo Garcia Manero, MD, Tapan M. Kadia, MD, Elias J. Jabbour, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 3887.

https://doi.org/10.1182/blood.V122.21.3887.3887

Published: 2013

Journal Articles

A Phase II Study Of Aprepitant As Anti-Emetic Prophylaxis In Patients Receiving Induction Chemotherapy For AML

Joseph Brandwein, MD, FRCPC, Karen W.L. WL Yee, MD, Andre C Schuh, MD, Vikas Gupta, MD, FRCP, FRCPath, Jack T Seki, PharmD

Blood (2013) 122 (21): 5035.

https://doi.org/10.1182/blood.V122.21.5035.5035

Published: 2013

Journal Articles

A Randomized Controlled Study Evaluating The Efficacy Of Aprepitant For Highly Emetogenic Chemotherapies In Hematological Malignancies

Ryo Nasu, Dr, Yasuhito Nannya, MD, PhD, Akihide Yoshimi, MD, PhD, Masataka Hosoi, M.D., Ph.D., Kouki Ueda, MD, PhD, Yumiko Yoshiki, MD, PhD, Shunya Arai, MD, PhD, Akihito Shinohara, M.D., Ph.D., Fumihiko Nakamura, MD, PhD, Mineo Kurokawa, MD, PhD

Blood (2013) 122 (21): 1790.

https://doi.org/10.1182/blood.V122.21.1790.1790

Published: 2013

Journal Articles

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

Saroj Vadhan-Raj, MD, Ivan Spasojevic, Ph.D., Xiao Zhou, MD, PHD, Jorge E Romaguera, MD, Michelle A. Fanale, MD, Luis E Fayad, MD, Nathan H. Fowler, MD, Auris Huen, PHARMD, F.B. Hagemeister, MD, Maria Alma Rodriguez, MD, Sattva S. Neelapu, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry W Kwak, MD, PhD

Blood (2011) 118 (21): 1613.

https://doi.org/10.1182/blood.V118.21.1613.1613

Published: 2011

Journal Articles

Aprepitant (Emend®) Significantly Increases Sirolimus Levels In Patients Undergoing Allogeneic Hematopoietic Stem Cell transplantation.

Sepideh Shayani, Pharm.D., Joycelynne Palmer, PhD, Tracey Stiller, Chan Holly, Pharm. D., Svetlana Keuylian, Pharm.D., Pablo Miguel Parker, M.D., Stephen Forman, MD, Ryotaro Nakamura, MD

Blood (2010) 116 (21): 1311.

https://doi.org/10.1182/blood.V116.21.1311.1311

Published: 2010

Journal Articles

Combined Use of Multi-Day Doses of Palonosetron and Aprepitant with Low Dose Dexamethasone In Prevention of Nausea and Emesis Among Patients with Multiple Myeloma and Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplant (ASCT): A Pilot Study

Delva Deauna-Limayo, MD, Omar Aljitawi, MD, Siddhartha Ganguly, MD, Sunil Abhyankar, MD, Jo Wick, Joseph McGuirk, DO

Blood (2010) 116 (21): 1335.

https://doi.org/10.1182/blood.V116.21.1335.1335

Published: 2010

Journal Articles

Aprepitant Vs. Placebo Plus Oral Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Associated with Highly Emetogenic Preparative Regimens Prior to Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Double-Blind Phase III Trial.

Patrick Stiff, MD, Mary Fox-Geiman, PharmD, Karen Kiley, MSN, NP, Nancy Porter, MSN, APN, Karen Rychlik, BA, Donna Fletcher-Gonzalez, PharmD, Amir Toor, MD, Scott E. Smith, MD, PhD, Tulio Rodriguez, MD

Blood (2009) 114 (22): 2267.

https://doi.org/10.1182/blood.V114.22.2267.2267

Published: 2009

Journal Articles

Prolonged Administration of Aprepitant Does Not Increase Toxicity in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplant.

Mehnaz Junagadhwalla, MD, Joanne Chilton, CRA, Teresa Gentile, MD, PhD

Blood (2005) 106 (11): 5329.

https://doi.org/10.1182/blood.V106.11.5329.5329

Published: 2005

Journal Articles

Evaluation of Aprepitant for Treatment of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting in Patients Undergoing Autologous Stem Cell Transplantation.

Chad M. Barnett, PharmD, Michael S. Oholendt, PharmD, Uday Popat, MD, George Carrum, MD, Helen E. Heslop, MD

Blood (2004) 104 (11): 5041.

https://doi.org/10.1182/blood.V104.11.5041.5041

Published: 2004

NARROW

Machine Learning Based Predictive Model of 5-Year Survival in Multiple Myeloma Autologous Transplant Patients

Prophylaxis of Chemotherapy-Induced Nausea and Vomiting with Fosaprepitant and Granisetron in Pediatric Patients after Allogeneic HSCT

Sinusoidal Obstruction Syndrom (SOS): Warning about Autologous Stem Cell Transplantation (ASCT) Preceded By Regimens Containing Oxaliplatin

Safety and Efficacy of Single-Dose Intravenous Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients with Hematooncological Malignancies after Moderate and High Emetogenic Chemotherapy

Antiemetic Prophylaxis with Granisetron and Fosaprepitant during Moderate and High Emetogenic Chemotherapy in Pediatric Patients

T-Cell Depleted HLA-Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT) Followed By Donor Lymphocyte Infusion with T Cells Transduced with the Inducible Caspase 9 (iC9) Suicide Gene in Children with Hematological Malignancies

A Randomized Trial of Olanzapine and Palonosetron versus Infused Ondansetron for the Treatment of Chemotherapy Induced Nausea and Vomiting in Patients Undergoing Hematopoietic Stem Cell Transplantation

Phase II, Open Label, Randomized Comparative Trial Of Ondansetron Alone Versus The Combination Of Ondansetron Plus Aprepitant For The Prevention Of Nausea and Vomiting In Patients (Pts) With Hematological Malignancies Receiving Regimens Containing High Dose Cytarabine

A Phase II Study Of Aprepitant As Anti-Emetic Prophylaxis In Patients Receiving Induction Chemotherapy For AML

A Randomized Controlled Study Evaluating The Efficacy Of Aprepitant For Highly Emetogenic Chemotherapies In Hematological Malignancies

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

Aprepitant (Emend®) Significantly Increases Sirolimus Levels In Patients Undergoing Allogeneic Hematopoietic Stem Cell transplantation.

Combined Use of Multi-Day Doses of Palonosetron and Aprepitant with Low Dose Dexamethasone In Prevention of Nausea and Emesis Among Patients with Multiple Myeloma and Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplant (ASCT): A Pilot Study

Aprepitant Vs. Placebo Plus Oral Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Associated with Highly Emetogenic Preparative Regimens Prior to Hematopoietic Stem Cell Transplantation: A Prospective, Randomized Double-Blind Phase III Trial.

Prolonged Administration of Aprepitant Does Not Increase Toxicity in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplant.

Evaluation of Aprepitant for Treatment of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting in Patients Undergoing Autologous Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only